Serum chemerin is increased in patients with chronic plaque psoriasis and normalizes following treatment with infliximab

British Journal of Dermatology

Volumn 168, Issue 4, 2013, Pages 749-755

  Gisondi, P ^a   Lora, V ^a   Bonauguri, C ^b   Russo, A ^b   Lippi, G ^b   Girolomoni, G ^a  

^a UNIVERSITY OF VERONA   (Italy)

^b Parma Hospital   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; C REACTIVE PROTEIN; CHEMERIN; CHOLESTEROL; GAMMA GLUTAMYLTRANSFERASE; GLUCOSE; INFLIXIMAB; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; RESISTIN; TRIACYLGLYCEROL;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GLUCOSE BLOOD LEVEL; HUMAN; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PSORIASIS VULGARIS; PSORIATIC ARTHRITIS; TREATMENT DURATION;

ADIPOKINES; ANTIBODIES, MONOCLONAL; C-REACTIVE PROTEIN; CASE-CONTROL STUDIES; CHEMOKINES; CHRONIC DISEASE; DERMATOLOGIC AGENTS; FEMALE; HUMANS; MALE; MIDDLE AGED; PSORIASIS; TREATMENT OUTCOME;

EID: 84875430429     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/bjd.12118     Document Type: Article

References (42)

1. Sterry W, Strober BE, Menter A,. Obesity in psoriasis: the metabolic, clinical and therapeutic implications. Report of an interdisciplinary conference and review. Br J Dermatol 2007; 157: 649-55.
2. Gisondi P, Tessari G, Conti A, et al. Prevalence of metabolic syndrome in patients with psoriasis: a hospital-based case-control study. Br J Dermatol 2007; 157: 68-73.
3. Gisondi P, Targher G, Zoppini G, et al. Non-alcoholic fatty liver disease in patients with chronic plaque psoriasis. J Hepatol 2009; 51: 758-64.
4. Herron MD, Hinckley M, Hoffman MS, et al. Impact of obesity and smoking on psoriasis presentation and management. Arch Dermatol 2005; 141: 1527-34.
5. Soltani-Arabshahi R, Wong B, Feng BJ, et al. Obesity in early adulthood as a risk factor for psoriatic arthritis. Arch Dermatol 2010; 146: 721-6.
6. Davidovici BB, Sattar N, Prinz JC, et al. Psoriasis and systemic inflammatory diseases: potential mechanistic links between skin disease and co-morbid conditions. J Invest Dermatol 2010; 130: 1785-96.
7. Naldi L, Addis A, Chimenti S, et al. Impact of body mass index and obesity on clinical response to systemic treatment for psoriasis. Evidence from the Psocare project. Dermatology 2008; 217: 365-73.
8. Wellen KE, Hotamisligil GS,. Obesity-induced inflammatory changes in adipose tissue. J Clin Invest 2003; 112: 1785-8.
9. Osborn O, Olefsky JM,. The cellular and signaling networks linking the immune system and metabolism in disease. Nat Med 2012; 18: 363-74.
10. Gualillo O, González-Juanatey JR, Lago F,. The emerging role of adipokines as mediators of cardiovascular function: physiologic and clinical perspectives. Trends Cardiovasc Med 2007; 17: 275-83.
11. Gerdes S, Rostami-Yazdi M, Mrowietz U,. Adipokines and psoriasis. Exp Dermatol 2011; 20: 81-7.
12. Albanesi C, Scarponi C, Pallotta S, et al. Chemerin expression marks early psoriatic skin lesions and correlates with plasmacytoid dendritic cell recruitment. J Exp Med 2009; 206: 249-58.
13. Wang B, Trayhurn P,. Acute and prolonged effects of TNF-alpha on the expression and secretion of inflammation-related adipokines by human adipocytes differentiated in culture. Pflugers Arch 2006; 452: 418-27.
14. Pathirana D, Ormerod AD, Saiag P, et al. European S3-guidelines on the systemic treatment of psoriasis vulgaris. J Eur Acad Dermatol Venereol 2009; 23 (Suppl. 2): 1-70.
15. Targher G, Bertolini L, Padovani R, et al. Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients. Diabetes Care 2007; 30: 1212-18.
16. Feldman SR,. A quantitative definition of severe psoriasis for use in clinical trials. J Dermatolog Treat 2004; 15: 27-9.
17. Taylor W, Gladman D, Helliwell P, et al. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum 2006; 54: 2665-73.
18. de Alwis NM, Day CP,. Non-alcoholic fatty liver disease: the mist gradually clears. J Hepatol 2008; 48 (Suppl. 1): S104-12.
19. Yoshimura T, Oppenheim JJ,. Chemerin reveals its chimeric nature. J Exp Med 2008; 205: 2187-90.
20. Wittamer V, Franssen JD, Vulcano M, et al. Specific recruitment of antigen-presenting cells by chemerin, a novel processed ligand from human inflammatory fluids. J Exp Med 2003; 198: 977-85.
21. Yamawaki H, Kameshima S, Usui T, et al. A novel adipocytokine, chemerin exerts anti-inflammatory roles in human vascular endothelial cells. Biochem Biophys Res Commun 2012; 423: 152-7.
22. Albanesi C, Scarponi C, Bosisio D, et al. Immune functions and recruitment of plasmacytoid dendritic cells in psoriasis. Autoimmunity 2010; 43: 215-19.
23. Weigert J, Obermeier F, Neumeier M, et al. Circulating levels of chemerin and adiponectin are higher in ulcerative colitis and chemerin is elevated in Crohn's disease. Inflamm Bowel Dis 2010; 16: 630-7.
24. Eisinger K, Bauer S, Schäffler A, et al. Chemerin induces CCL2 and TLR4 in synovial fibroblasts of patients with rheumatoid arthritis and osteoarthritis. Exp Mol Pathol 2012; 92: 90-6.
25. Chu SH, Lee MK, Ahn KY, et al. Chemerin and adiponectin contribute reciprocally to metabolic syndrome. PLoS ONE 2012; 7: e34710.
26. Gisondi P, Cotena C, Tessari G, et al. Anti-tumour necrosis factor-alpha therapy increases body weight in patients with chronic plaque psoriasis: a retrospective cohort study. J Eur Acad Dermatol Venereol 2008; 22: 341-4.
27. Saraceno R, Schipani C, Mazzotta A, et al. Effect of anti-tumor necrosis factor-alpha therapies on body mass index in patients with psoriasis. Pharmacol Res 2008; 57: 290-5.
28. Reilly MP, Lehrke M, Wolfe ML, et al. Resistin is an inflammatory marker of atherosclerosis in humans. Circulation 2005; 111: 932-9.
29. Senolt L, Housa D, Vernerová Z, et al. Resistin in rheumatoid arthritis synovial tissue, synovial fluid and serum. Ann Rheum Dis 2007; 66: 458-63.
30. Konrad A, Lehrke M, Schachinger V, et al. Resistin is an inflammatory marker of inflammatory bowel disease in humans. Eur J Gastroenterol Hepatol 2007; 19: 1070-4.
31. Johnston A, Arnadottir S, Gudjonsson JE, et al. Obesity in psoriasis: leptin and resistin as mediators of cutaneous inflammation. Br J Dermatol 2008; 159: 342-50.
32. Son YM, Ahn SM, Kim GR, et al. Resistin enhances the expansion of regulatory T cells through modulation of dendritic cells. BMC Immunol 2010; 30: 11-33.
33. Cho Y, Lee SE, Lee HC, et al. Adipokine resistin is a key player to modulate monocytes, endothelial cells, and smooth muscle cells, leading to progression of atherosclerosis in rabbit carotid artery. J Am Coll Cardiol 2011; 57: 99-109.
34. Fukuhara A, Matsuda M, Nishizawa M, et al. Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science 2005; 307: 426-30.
35. Moschen AR, Kaser A, Enrich B, et al. Visfatin, an adipocytokine with proinflammatory and immunomodulating properties. J Immunol 2007; 178: 1748-58.
36. Koczan D, Guthke R, Thiesen HJ, et al. Gene expression profiling of peripheral blood mononuclear leukocytes from psoriasis patients identifies new immune regulatory molecules. Eur J Dermatol 2005; 4: 251-7.
37. Tilg H, Moschen AR,. Role of adiponectin and PBEF/visfatin as regulators of inflammation: involvement in obesity-associated diseases. Clin Sci (Lond) 2008; 114: 275-88.
38. Ridker PM, Buring JE, Cook NR, et al. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14,719 initially healthy American women. Circulation 2003; 107: 391-7.
39. Ohtsuka T,. The relation between high-sensitivity C-reactive protein and maximum body mass index in patients with psoriasis. Br J Dermatol 2008; 158: 1141-3.
40. Gisondi P, Malerba M, Malara G, et al. C-reactive protein and markers for thrombophilia in patients with chronic plaque psoriasis. Int J Immunopathol Pharmacol 2010; 23: 1195-202.
41. Strober B, Teller C, Yamauchi P, et al. Effects of etanercept on C-reactive protein levels in psoriasis and psoriatic arthritis. Br J Dermatol 2008; 159: 322-30.
42. Nakajima H, Nakajima K, Nagano Y, et al. Circulating level of chemerin is upregulated in psoriasis. J Dermatol Sci 2010; 60: 45-7.